Overview

• The consolidated proceeding in the Eastern District of Pennsylvania now includes 2,190 filed cases as of Aug. 1, and new individual suits, including a New Jersey claim by Todd Engel alleging irreversible vision loss, continue to be filed.
• Plaintiffs contend GLP-1 drugs such as Ozempic, Wegovy, Mounjaro and Rybelsus caused gastroparesis, intestinal blockages, sudden vision loss, gallbladder disease, pancreatitis and kidney injury, and that warnings were inadequate.
• Recent studies show mixed signals on eye risks, with one JAMA analysis noting a slight rise in NAION and another finding no significant NAION link but a small increase in diabetic retinopathy, while Novo Nordisk says no causal link is proven.
• Regulators have required updated product labels to advise users of additional risks associated with these medicines.
• Analyst estimates suggest potential liabilities for Novo Nordisk could exceed $2 billion if plaintiffs prevail.